In Brief: Pharmacia & Upjohn's Azulfidine EN-Tabs
Pharmacia & Upjohn's Azulfidine EN-Tabs: Rheumatoid arthritis indication clears FDA Oct. 18. The supplemental NDA was filed April 29, 1994 for "treatment of rheumatoid arthritis in patients who have responded inadequately to or are intolerant of analgesics or other non-steroidal anti-inflammatory drugs." Azulfidine EN-Tabs are given in a total daily dose of 2g, twice or three times daily...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth